AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05034757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWT twice
Description: ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder
Study NCT01688934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V116517 50-mg tablets
Description: Taken orally twice daily
Study NCT01688934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V116517 30-mg tablets
Description: Taken orally twice daily
Study NCT01688934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 500-mg capsules
Description: Taken orally twice daily
Study NCT01688934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
Study NCT01688934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
Study NCT01688934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
Study NCT02169115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: 150mg, s.c., every 4 weeks
Study NCT02169115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: 300mg, s.c., every 4 weeks
Study NCT02169115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, s.c., every 4 weeks
Study NCT00530725 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chest drainage
Description: may be a chest tube of chest drainage procedure of any type (ie formal tube, pig-tail catheter, etc)
Study NCT00530725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: close clinical observation
Description: close clinical observation in an operating room or intensive care unit without active intervention
Study NCT05029297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Study NCT05029297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Study NCT04690881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychodrama group psychotherapy
Description: In order to reduce the fear of cihildbirth, pregnant women are given 90 minutes right after the training in addition to the routine pregnancy training. In the psychodrama-based pregnancy education program, fear of childbirth were assesment by sociometric measurement in order to increase the awareness of pregnant women about birth fear levels in the first week. Afterwards, they were given the opportunity to express themselves about the factors that may cause fear in pregnant women (their previous traumatic experiences, negative prejudices about childbirth, etc). The group members shared about their process in the first session and the session was ended. The session was evaluated with other researchers. In the following sessions, in order to strengthen their coping with the fear of childbirth, besides psychodrama warm-up games, the basic techniques of psychodrama, role switching, matching and mirror were used in protogonist works.
Study NCT00977522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03463275
Description: 30 mg Controlled Release tablet BID for 12 weeks
Study NCT00977522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet BID
Study NCT03397056 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The Questionnaire is provided in the links at the end of the declaration.
Study NCT02849093 — intervention group
Intervention type: OTHER
Intervention: Non-invasive OCT imaging
Description: Optical Coherence Tomography (OCT) to capture high resolution cross-sectional images of tissue microstructures using infra-red radiation.
Study NCT05099198 — intervention group
Intervention type: DRUG
Intervention: Sitagliptin
Description: Sitagliptin dispensing claim is used as the reference
Study NCT05099198 — intervention group
Intervention type: DRUG
Intervention: Glimepiride
Description: Glimepiride dispensing claim is used as the reference
Study NCT02995005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: 300 mg daily
Study NCT01499628 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Reading
Description: Participant attends once a week for three weeks for a 45 minute appointment of supervised reading using appropriate spectacles and/or glasses
Study NCT01499628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVT at the PRL
Description: Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
Study NCT01499628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVT at the TRL
Description: Participant attends once a week for three weeks for a 45 minute appointment of TRL training using the MAIA microperimeter and then further reading using magnifiers and/or spectacles.
Study NCT02184026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure, Relaxation, & Rescripting Therapy-Child
Description: Exposure, Relaxation, \& Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing, child-friendly exposure to the trauma-nightmare, and rescription.
Study NCT00858845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Patch
Description: A clonidine patch (0.1 mg/week) to be worn for a period of 3 months.
Study NCT00858845 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Patch
Description: A matching placebo patch to be worn for a period of 3 months.
Study NCT04383886 — intervention group
Intervention type: OTHER
Intervention: stress and anxiety questionnaire
Description: Emergency department staff will be asked to fill in questionnaires in order to measure their stress and anxiety level, their propensity to have a burn-out, their consumption of psychoactive substances such as alcohol, tobacco, coffee or anxiolytic, their sleep disorder.
Study NCT03452319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pretraining
Description: Increased physical activity, and daily strength training and breathing exercises.
Study NCT03452319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Preoperative information
Study NCT00367861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interruption of Glivec®
Description: interruption of Glivec®
Study NCT01794039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT01794039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01794039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study NCT00622414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV
Study NCT02458586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary intervention / counseling
Description: dietary counseling and daily intake of 50 g of dietary oil over a period of 8 weeks
Study NCT02458586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention / counseling
Description: dietary counseling and daily intake of 50 g of dietary oil over a period of 8 weeks
Study NCT04411966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-fluorothymidine
Description: Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes at least 10 days prior to systemic chemotherapy, and at least 10 days after first and second cycles of systemic chemotherapy.
Study NCT03421834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation of ventricular tachycardia
Description: Catheter ablation with a uniform mapping system, procedural endpoint, and definition of acute procedural success.
Study NCT03421834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical treatment
Description: Optimal guidelines-based heart failure treatment and antiarrhythmic drugs. Antiarrhythmics will be avoided if possible in the ablation group.
Study NCT03421834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal medical treatment
Description: Optimal guidelines-based heart failure treatment and antiarrhythmic drugs. Antiarrhythmics will be avoided if possible in the ablation group.
Study NCT00127946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AMNIOECHANGE
Description: The AMNIOECHANGE consists of a transabdominal infusion of saline (heated to 37 ° C) with a needle 18 or 20 gauge under ultrasound monitoring while avoiding the placenta. In the case of a normal amniotic fluid, it must be replaced volume per volume of saline (eg depending on the tank where the puncture is made, it can be 300 per 300 ml). The total amount of amniotic fluid exchange is 600-900 ml. In cases of oligohydramnios, the AMNIOECHANGE results in a normalized volume of amniotic fluid.
Study NCT00127946 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: AMNIOECHANGE
Description: The AMNIOECHANGE consists of a transabdominal infusion of saline (heated to 37 ° C) with a needle 18 or 20 gauge under ultrasound monitoring while avoiding the placenta. In the case of a normal amniotic fluid, it must be replaced volume per volume of saline (eg depending on the tank where the puncture is made, it can be 300 per 300 ml). The total amount of amniotic fluid exchange is 600-900 ml. In cases of oligohydramnios, the AMNIOECHANGE results in a normalized volume of amniotic fluid.
Study NCT05497362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: 2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 15 minutes. Speech therapy was delivered simultaneously.
Study NCT05497362 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: 2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 30 sec. Speech therapy was delivered simultaneously.
Study NCT05246462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Logotherapy
Description: In this study, the experimental group received seven-session logotherapy-based interviews on making sense of life, while the control group received only routine nursing care. In this study, Personal Meaning Oriented Psychotherapy (PMOP) was used to structure interviews on making sense of life based on Logotherapy and enhance the sense of meaning in cancer patients, share their concerns, experiences, and feelings about diagnosis-treatment, have their difficulties defined, maintain, and develop their sense of purpose and responsibility.
Study NCT03744143 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: longitudinal suture
Description: Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a longitudinal suture
Study NCT03744143 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: transverse suture
Description: Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a transverse suture
Study NCT03744143 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Removal of vaginal endometriotic nodule
Description: Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, or vaginal technique, isolating the nodule through the vagina.
Study NCT03671590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1701
Description: Oral daily dose
Study NCT03671590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Oral Daily Dose
Study NCT03671590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: IV infusion
Study NCT04678206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: Oral administration of BLU-5937 Tablets
Study NCT04678206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of matching placebo for BLU-5937 Tablets
Study NCT02258984 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mespere Venus 1000 Non-Invasive CVP System
Description: The Venus 1000 CVP System is a non-invasive central venous pressure measurement system that utilizes the proven science of NIRS. Approved by FDA, received Health Canada Medical Device Licence and CE Marked, the Venus 1000 has been proven to be clinically equivalent to measurements made via right heart catheterization.
Study NCT02166879 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Participants complete anesthesia questionnaire before elective surgical procedure.
Study NCT05415657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 mg per 6 month were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
Study NCT05415657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equal volume of saline (0.9%) as placebo Q6M were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
Study NCT04292951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid and inotropic/vasoactive management protocol
Description: GDT protocol: keep SVV 10-13% and give fluid when SVV > 13%, give inotropic to maintain CI 2.5-4 L/min/m2, give vasoactive drugs to maintain SVRI 1,900-2,400 dynes-sec/cm-5/m2 Control protocol: keep CVP 8-12 mmHG and give fluid when CVP \< 8 mmHg, give inotropic/vasoactive to maintain normal blood pressure and heart rate
Study NCT04292951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid and inotropic/vasoactive management protocol
Description: GDT protocol: keep SVV 10-13% and give fluid when SVV > 13%, give inotropic to maintain CI 2.5-4 L/min/m2, give vasoactive drugs to maintain SVRI 1,900-2,400 dynes-sec/cm-5/m2 Control protocol: keep CVP 8-12 mmHG and give fluid when CVP \< 8 mmHg, give inotropic/vasoactive to maintain normal blood pressure and heart rate
Study NCT00697164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Admission, day 1, day 2 3 days
Study NCT00697164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Erythropoietin, 1500 U/kg/day Admission, day 1, day 2 3 days
Study NCT01858948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega
Description: Omega-3 supplements
Study NCT01858948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar in shape and color to Omega supplements
Study NCT01858948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: Prior to randomization to Omega/placebo, patients were started on 100 mg BID of quetiapine, and the dose adjusted based on tolerability and response. The quetiapine target dose is 400-600 mg.
Study NCT01858948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quetiapine fumarate
Description: Prior to randomization to Omega/placebo, patients were started on 100 mg BID of quetiapine, and the dose adjusted based on tolerability and response. The quetiapine target dose is 400-600 mg.
Study NCT03415880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive workshops LiPAT intervention group
Description: Workshops include practical behavior change strategies and address barriers to movement, awareness of the immediate benefits of movement and implementation-intentions. Participants will be encouraged to cultivate a learning mind-set in order to better tolerate potential set-backs and to apply strategies such as pre-planning their week to incorporate physical activity, engaging their social network, and setting up systems and habits. Participants' progress in changing their physical activity patterns which will be compared and discussed.
Study NCT03415880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist-worn feedback physical activity monitor
Description: Participants receive the feedback monitor (Fitbit inspire®; commercially available consumer product (https://www.fitbit.com/inspire)
Study NCT03415880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone application LiPAT
Description: With a cloud-based platform the iHealth data is synchronized with a mobile phone app developed by the research team. The app is designed to help the participant to self-monitor their physical activity levels and includes information on total activity and number of steps taken.
Study NCT03415880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Coaching
Description: participants in the intervention group will receive telephone coaching during the first 3 months of the intervention. Telephone coaching will be conducted twice in the first month and once each in months two and three. The researcher will enquire about the progress with increasing LiPA, about the experiences of applying the strategies discussed during workshops, and about the experience with Fitbit Inspire® and the corresponding app. If needed, the coach will offer suggestions to improve goal adherence.
Study NCT03415880 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Workshops control group LiPAT
Description: During the first 6 months of the study (the intervention period) participants in the control group will attend 4 workshops in which the benefits of physical activity and the health-risks of sedentary behavior will be discussed. Additionally, information will be provided on healthy lifestyle for patients with type 2 diabetes.
Study NCT00998946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Pralatrexate injection administered as intravenous (IV) push
Study NCT00998946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1 mg intramuscular (IM) injection
Study NCT00998946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Oral 1 mg tablet
Study NCT04227600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-171 (lepunafusp alfa)
Description: IV infusion
Study NCT02693418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acidform 5 g
Description: Effect of 5 g vaginally administered Acidform on pH over 7 days
Study NCT02693418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 4 g
Description: Effect of 4 g of vaginally administered HEC placebo gel on pH over 7 days
Study NCT02693418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acidform 4 g
Description: Effect of 4 g vaginally administered Acidform on pH over 7 days
Study NCT02693418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acidform 3 g
Description: Effect of 3 g vaginally administered Acidform on pH over 7 days
Study NCT01627717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (5 days)
Description: Subjects will receive maraviroc 150 mg tablets (1 tablet) every 12 hours from days 1 to 5 inclusively.
Study NCT01627717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc and boceprevir (14 days)
Description: From days 6 to 19, inclusively, boceprevir 800 mg (4 capsules of 200 mg) every 8 hours with food will be given with maraviroc 150 mg (1 tablet of 150 mg) every 12 hours.
Study NCT03284554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Encapsulated nutrients
Description: Amino acid + Lipid; Probiotic bacteria
Study NCT03284554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Non-encapsulated nutrients
Description: Amino acid + Lipid; Probiotic bacteria
Study NCT03284554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nutrient not expected to stimulate release of GLP-1 and PYY
Study NCT03564262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sodium Meal (138 mg sodium)
Description: One Low Sodium Meal
Study NCT03564262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Sodium Meal (1,495 mg sodium)
Description: One High Sodium Meal
Study NCT01228045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab in Combination with TS-ONE and cisplatin
Description: Subjects will receive treatment that combined TS-ONE, cisplatin and trastuzumab every 3 weeks in this study. This 3 weeks period of time is called a cycle. The cycle will be repeated until subject experience disease progression or unbearable toxicities or they choose to withdraw from the study. Each cycle is numbered in order.